Barclays PLC Stoke Therapeutics, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 80,112 shares of STOK stock, worth $649,708. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,112

Previous 79,740 0.47%

Holding current value

$649,708

Previous $980,000 9.8%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$10.8 - $13.92 $4,017 - $5,178	372 Added 0.47%	80,112 $884,000
Q3 2024 Nov 15, 2024	BUY	$12.24 - $15.92 $578,205 - $752,044	47,239 Added 145.35%	79,740 $980,000
Q2 2024 Aug 14, 2024	BUY	$11.03 - $17.52 $131,003 - $208,085	11,877 Added 57.59%	32,501 $439,000
Q1 2024 May 15, 2024	SELL	$4.12 - $14.17 $76,825 - $264,227	-18,647 Reduced 47.48%	20,624 $278,000
Q4 2023 Feb 15, 2024	BUY	$3.37 - $5.4 $103,900 - $166,487	30,831 Added 365.3%	39,271 $206,000
Q3 2023 Nov 07, 2023	SELL	$3.78 - $11.99 $24,150 - $76,604	-6,389 Reduced 43.08%	8,440 $33,000
Q2 2023 Aug 03, 2023	SELL	$7.93 - $13.82 $63,685 - $110,988	-8,031 Reduced 35.13%	14,829 $157,000
Q1 2023 May 04, 2023	BUY	$7.65 - $10.38 $33,790 - $45,848	4,417 Added 23.95%	22,860 $190,000
Q4 2022 Feb 13, 2023	BUY	$7.07 - $15.69 $55,711 - $123,637	7,880 Added 74.6%	18,443 $170,000
Q3 2022 Nov 03, 2022	BUY	$12.56 - $22.53 $8,063 - $14,464	642 Added 6.47%	10,563 $135,000
Q2 2022 Aug 12, 2022	BUY	$10.36 - $23.93 $54,244 - $125,297	5,236 Added 111.76%	9,921 $131,000
Q1 2022 May 16, 2022	SELL	$17.19 - $26.1 $317,739 - $482,432	-18,484 Reduced 79.78%	4,685 $98,000
Q4 2021 Feb 14, 2022	BUY	$18.11 - $30.72 $253,540 - $430,080	14,000 Added 152.69%	23,169 $556,000
Q3 2021 Nov 09, 2021	SELL	$23.65 - $34.44 $43,610 - $63,507	-1,844 Reduced 16.74%	9,169 $233,000
Q2 2021 Aug 13, 2021	SELL	$30.53 - $41.09 $202,536 - $272,591	-6,634 Reduced 37.59%	11,013 $370,000
Q1 2021 May 13, 2021	BUY	$36.08 - $69.81 $451,505 - $873,602	12,514 Added 243.8%	17,647 $686,000
Q4 2020 Feb 11, 2021	SELL	$33.62 - $61.93 $56,548 - $104,166	-1,682 Reduced 24.68%	5,133 $318,000
Q3 2020 Nov 12, 2020	SELL	$22.23 - $37.48 $70,380 - $118,661	-3,166 Reduced 31.72%	6,815 $229,000
Q2 2020 Aug 12, 2020	BUY	$20.26 - $29.73 $76,643 - $112,468	3,783 Added 61.04%	9,981 $239,000
Q1 2020 May 13, 2020	SELL	$16.8 - $34.15 $61,118 - $124,237	-3,638 Reduced 36.99%	6,198 $142,000
Q4 2019 Feb 10, 2020	BUY	$20.01 - $30.79 $76,738 - $118,079	3,835 Added 63.91%	9,836 $278,000
Q3 2019 Nov 14, 2019	BUY	$20.53 - $37.72 $104,436 - $191,881	5,087 Added 556.56%	6,001 $129,000
Q2 2019 Aug 14, 2019	BUY	$25.53 - $29.17 $23,334 - $26,661	914 New	914 $27,000

Others Institutions Holding STOK

# of Institutions

136

Shares Held

57.3M

Call Options Held

5.7K

Put Options Held

24.4K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $320M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account